Is BromSite More Effective Than Bromday Eye Drops For Postoperative Inflammation and Reduction of Ocular Pain?
October 7, 2011
Earlier this week, InSite Vision Incorporated announced positive top-line results from a Phase 2 clinical study comparing the tissue penetration profile of its BromSite (ISV-303) with ISTA Pharmaceuticals’ Bromday (bromfenac ophthalmic solution) 0.09% eye drops.
BromSite combines a lower dose (0.075%) of the non-steroidal anti-inflammatory drug (NSAID) bromfenac with InSite Vision’s DuraSite drug delivery technology to reduce the pain and inflammation associated with ocular surgery.
The randomized, double-masked, two-arm study evaluated the aqueous humor concentration of once-daily doses of BromSite versus Bromday in 58 subjects. Subjects were dosed two days before and the morning of the day of cataract surgery. Study results showed that the mean concentration of bromfenac in the aqueous humor of patients in BromSite’s group was more than twice greater compared to those patients in Bromday’s group.
Click here to read the press release.
You might also enjoy...
- ISTA Pharmaceuticals Announces Positive Results for Xibrom
- ISTA Pharmaceuticals Announces Phase 3 Results for PROLENSA(TM) Eye Drops for Treatment of Pain and Inflammation After Cataract Surgery
- InSite Vision Commences Phase 1/2 Clinical Study of ISV-303 for Post-Surgical Ocular Pain and Swelling Following Cataract and Other Surgeries
- Once Daily Bromday Drops From ISTA Approved For Cataract Patients
- Lux Biosciences’ Voclosporin Phase II/III Results Presented at AAO
Jump down to form below to submit your own comments